November 5, 2018 04:29 PM EST
Pharma

Af­ter play­ing pos­sum in I/O, Eli Lil­ly shows new signs of life with $40M-plus cash dis­cov­ery deal for NextCure

John Carroll

Editor & Founder

Eli Lil­ly was es­sen­tial­ly a no-show in the ini­tial scram­ble to slice up a mas­sive, mega-block­buster mar­ket for im­muno-on­col­o­gy drugs. But they’ve been show­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times